John P Fruehauf

List of Publications by Year
in descending order

33 papers	2,498 citations	411340 20 h-index	488211 31 g-index
35 all docs	35 docs citations	35 times ranked	4534 citing authors

#	Article	IF	Citations
1	Reactive Oxygen Species: A Breath of Life or Death?: Fig. 1.. Clinical Cancer Research, 2007, 13, 789-794.	3.2	837
2	Redox Regulation in Human Melanocytes and Melanoma. Pigment Cell & Melanoma Research, 2001, 14, 148-154.	4.0	196
3	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology, 2012, 30, 34-41.	0.8	172
4	Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling. Cancer Research, 2009, 69, 4484-4492.	0.4	125
5	Mathematical modeling of cancer progression and response to chemotherapy. Expert Review of Anticancer Therapy, 2006, 6, 1361-1376.	1.1	105
6	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 7462-7469.	3.2	100
7	Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis, 2010, 13, 305-315.	3.7	98
8	Association between in Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients. Gynecologic Oncology, 2002, 87, 8-16.	0.6	89
9	Reactive oxygen species: an Achillesâ€™ heel of melanoma?. Expert Review of Anticancer Therapy, 2008, 8, 1751-1757.	1.1	81
10	In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas. Clinical Cancer Research, 2006, 12, 4523-4532.	3.2	72
11	The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. Journal of Neuro-Oncology, 2001, 55, 195-204.	1.4	71
12	Lycopene Enhances Docetaxel's Effect in Castration-Resistant Prostate Cancer Associated with Insulin-like Growth Factor I Receptor Levels. Neoplasia, 2011, 13, 108-119.	2.3	71
13	Mutant p53 Correlates with Reduced Expression of Thrombospondin-1, Increased Angiogenesis, and Metastatic Progression in Melanoma. Cancer Detection and Prevention, 1998, 22, 185-194.	2.1	70
14	The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer. Clinical Cancer Research, 2005, 11, 3733-3742.	3.2	66
15	Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression. Cancer, 2007, 110, 2519-2527.	2.0	49
16	Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay. Breast Cancer Research and Treatment, 2001, 66, 225-237.	1.1	47
17	Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biology, 2013, 32, 123-132.	1.5	45
18	HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Molecular Cancer Research, 2019, 17, 1675-1686.	1.5	34

#	Article	IF	Citations
19	Melanin content and downregulation of glutathione S-transferase contribute to the action of l-buthionine-S-sulfoximine on human melanoma. Chemico-Biological Interactions, 1998, 111-112, 277-305.	1.7	26
20	Targeted Therapy in Ovarian Cancer. Journal of Oncology, 2010, 2010, 1-9.	0.6	22
21	Use of the Extreme Drug Resistance Assay to Evaluate Mechanisms of Resistance in Ovarian Cancer: Taxol Resistance and MDR-1 Expression. Contributions To Gynecology and Obstetrics, 1994, , 39-52.	0.1	20
22	A Prospective Blinded Study of the Predictive Value of an Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma. Journal of Neuro-Oncology, 2004, 66, 365-375.	1.4	18
23	Selective and Synergistic Activity of L-S,R-Buthionine Sulfoximine on Malignant Melanoma Is Accompanied by Decreased Expression of Glutathione-S-Transferase. Pigment Cell & Melanoma Research, 1997, 10, 236-249.	4.0	17
24	Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2018, 82, 353-360.	1.1	15
25	Redox-related antimelanoma activity of ATN-224. Melanoma Research, 2009, 19, 350-360.	0.6	13
26	A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomedicine and Pharmacotherapy, 2021, 143, 112226.	2.5	12
27	A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemotherapy and Pharmacology, 2013, 72, 263-267.	1.1	10
28	Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1081-1087.	1.1	8
29	EGFR function and detection in cancer therapy. Journal of Experimental Therapeutics and Oncology, 2006, 5, 231-46.	0.5	7
30	Patient-specific tumor biology-based selection of ovarian cancer therapy. Therapy: Open Access in Clinical Medicine, 2010, 7, 213-216.	0.2	1
31	Targeting epithelialâ€“mesenchymal transition: therapeutic reversal of the cancer stem cell phenotype. Therapy: Open Access in Clinical Medicine, 2011, 8, 737-740.	0.2	1
32	A Tale of Two Growth Factors. Pharmacotherapy, 2006, 26, 443-444.	1.2	0
33	Increased eIF4E Expression and Phosphorylation in Late Phase Chronic Myelogenous Leukemia Occurs in a Bcr-Abl-Dependent Manner, and Can Be Targeted by a Novel Mnk Kinase Inhibitor, CGP57380, To Overcome Imatinib-Resistance.. Blood, 2006, 108, 2193-2193.	0.6	0